Innovation and M&A to boost these stocks
There’s been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Overall, 12 mental health disorders affect 970 million people around the world — or one…
Bristol Myers Squibb (BMY) Q4 earnings report 2023
Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. Here’s what the company reported for the…
Big pharma Merck, Bristol Myers, J&J prepare to lose revenue
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a…
Stocks making the biggest moves midday: NKE, RKLB, BMY, NTES
Check out the companies making headlines in midday trading. Nike , Foot Locker — Shares of Nike plummeted 11.8% after the athletic apparel company slashed its revenue outlook and announced…
Bristol Myers Squibb to buy Karuna Therapeutics
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock popped more than 47% on…
NKE, BMY, COIN and more
Check out the companies making headlines in premarket trading. Nike — Shares tumbled 12.1% after the athletic retailer slashed its sales guidance and announced plans to cut costs by around…
Investors may be passing up three biopharma areas, Oppenheimer says
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically,…
Citi names top biotech stock picks for 2023
Biotech has been a “stock-pickers market” — and it may have just what it takes to remain one in 2023, according to Citi. “Biotech is currently a stock-pickers market, with…
Big pharma still favored, but good bets in biotech are out there
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The…